Small Cardioactive Peptide B SCPB

Research use only, not for human use.

Small Cardioactive Peptide B (SCPB), a neurally active peptide, stimulates adenylate cyclase activity in particulate fractions of both heart and gill tissues with EC50s of 0.1 and 1.0 μM, respectively.

Small Cardioactive Peptide B (SCPB), a neurally active peptide, stimulates adenylate cyclase activity in particulate fractions of both heart and gill tissues with EC50s of 0.1 and 1.0 μM, respectively.(In Vitro):Small cardioactive peptide B (SCPB) is a neurally active peptide endogenous to Aplysia. Small cardioactive peptide B (SCPB) possesses cardioexcitatory effects in Aplysia and reported a threshold concentration of 0.01 nM for both native and synthetic Small cardioactive peptide B (SCPB) stimulated effects on the isolated heart. Effects of Small Cardioactive Peptide B (SCPB) on the physiology of the isolated heart and gill preparations from the mollusc Aplysia californica were examined. In addition, the effects of Small Cardioactive Peptide B (SCPB) and FMRFamide (Phe-Met-Arg-Phe-NH2) on adenylate cyclase activity are compared in particulate fractions of heart and gill tissues, respectively. Small Cardioactive Peptide B (SCPB) is found to exert dose-dependent, reversible changes in cardiac activity when perfused through the isolated heart. The EC50 values effecting changes in heart rate and force of contraction are 0.03 and 0.3 nM, respectively; minimum concentrations find to effect changes in heart rate and force of contraction are normally 0.001 and 1 pM, respectively. When perfused through the isolated gill, Small Cardioactive Peptide B (SCPB) is found to suppress the gill withdrawal response amplitude with a threshold concentration of 0.01 pM and an EC50 value of 0.03 nM. Suppression of the gill withdrawal response amplitude by Small Cardioactive Peptide B (SCPB)is found to be dose dependent and reversible up to a concentration of 1nM. At higher concentrations, the suppression tended to persist irreversibly. Small Cardioactive Peptide B (SCPB) stimulates adenylate cyclase activity in particulate fractions of both heart and gill tissues with an EC50 of 0.1 and 1.0μM, respectively.

Small cardioactive peptide B (SCPB) is a neurally active peptide endogenous to Aplysia. Small cardioactive peptide B (SCPB) possesses cardioexcitatory effects in Aplysia and reported a threshold concentration of 0.01 nM for both native and synthetic Small cardioactive peptide B (SCPB) stimulated effects on the isolated heart. Effects of Small Cardioactive Peptide B (SCPB) on the physiology of the isolated heart and gill preparations from the mollusc Aplysia californica were examined. In addition, the effects of Small Cardioactive Peptide B (SCPB) and FMRFamide (Phe-Met-Arg-Phe-NH2) on adenylate cyclase activity are compared in particulate fractions of heart and gill tissues, respectively. Small Cardioactive Peptide B (SCPB) is found to exert dose-dependent, reversible changes in cardiac activity when perfused through the isolated heart. The EC50 values effecting changes in heart rate and force of contraction are 0.03 and 0.3 nM, respectively; minimum concentrations find to effect changes in heart rate and force of contraction are normally 0.001 and 1 pM, respectively. When perfused through the isolated gill, Small Cardioactive Peptide B (SCPB) is found to suppress the gill withdrawal response amplitude with a threshold concentration of 0.01 pM and an EC50 value of 0.03 nM. Suppression of the gill withdrawal response amplitude by Small Cardioactive Peptide B (SCPB)is found to be dose dependent and reversible up to a concentration of 1nM. At higher concentrations, the suppression tended to persist irreversibly. Small Cardioactive Peptide B (SCPB) stimulates adenylate cyclase activity in particulate fractions of both heart and gill tissues with an EC50 of 0.1 and 1.0μM, respectively.

——

——

Metabolic Enzyme/Protease

Adenylate Cyclase

EC50: 0.1 μM (adenylate cyclase, in heart tissues), 1.0 μM (adenylate cyclase, in gill tissues)

——

——

84746-43-0

1141.41

C52H80N14O11S2

>98% (HPLC)

In Vitro:?H2O : 50 mg/mL (43.81 mM)

——

Sequence:Met-Asn-Tyr-Leu-Ala-Phe-Pro-Arg-Met-NH2

(-20℃)

With Ice Pack

≥ 2 years